Inflation, PowellTestimony, Earnings Focus
This is a news story, published by Yahoo Finance, that relates primarily to Moderna news.
Moderna news
For more Moderna news, you can click here:
more Moderna newsNews about inflation
For more inflation news, you can click here:
more inflation newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like this article about inflation, you might also like this article about
more stock market analysis. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest market trend news, Inflation data news, news about inflation, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
resurgent retail trading waveInvesting.com
•Business
Business & Economics
1 Stock to Buy, 1 Stock to Sell This Week: Robinhood, Moderna

82% Informative
Robinhood, the commission-free trading app popular with retail investors, is set to report its fourth quarter earnings update after the closing bell on Wednesday at 4:05PM ET.
Robinhood 's strong financial health, robust outlook, and bullish analyst sentiment make it a compelling buy.
Moderna ’s shrinking revenue, expected losses, and weak financial score makes it a stock to sell.
MRNA stock ended Friday ’s session at $ 32.60 , not far from a recent 52-week low of $ 31.94 , which was the weakest level since April 2020 .
The biotech company is now facing revenue growth challenges with limited near-term catalysts to offset declining demand as vaccine sales continue to decline.
VR Score
82
Informative language
83
Neutral language
22
Article tone
formal
Language
English
Language complexity
52
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
6
Source diversity
2
Affiliate links
no affiliate links